Indian clot-buster drug enters phase-2 - Livemint
CSIR Developed Clot Specific Streptokinase Enters into Phase-2 Human Clinical Trials
Medical Schools at SBU, NYU Announce Collaboration with Nostrum Pharmaceuticals on New Pulmonary Treatment
CSIR lab in second licensing deal with US pharma company.
Nostrum Pharmaceuticals Obtains Worldwide Licensing Rights From IMTECH for Clinical Development of the Small Molecule Caerulomycin and Its Proprietary Derivatives for Their Novel Indication of Immunosuppression.
Nostrum Announces the Successful Completion of Early Proof-of-Concept Study for its Novel Clot Busting Therapeutic Protein
Best Viewed at 1024x768, IE 7.0
© Nostrum Pharmaceuticals LLC. 2008